CLINICAL TRIALS PROFILE FOR DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	Blood and Marrow Transplant Clinical Trials Network	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Cancer Institute (NCI)	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Marrow Donor Program	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	Medical College of Wisconsin	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.

Clinical Trial Conditions for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Candidiasis	5
Fungal Infection	4
Candidemia	3
Healthy	3

Condition MeSH

Condition MeSH for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Candidiasis	14
Mycoses	9
Infections	5
Infection	5

Clinical Trial Locations for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
United States	157
Canada	14
Brazil	5
Spain	4
Italy	4

Trials by US State

Trials by US State for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
California	9
North Carolina	8
Florida	8
Texas	8
Pennsylvania	8

Clinical Trial Progress for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	11
Phase 2	4

Clinical Trial Status

Clinical Trial Status for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	27
Not yet recruiting	4
Unknown status	3

Clinical Trial Sponsors for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Pfizer	4
Astellas Pharma Inc	3
National Cancer Institute (NCI)	3

Sponsor Type

Sponsor Type for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	45
Industry	25
NIH	10

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER: Clinical Trials, Market Analysis, and Forecast

Last updated: February 20, 2026

What Are the Recent Clinical Trial Developments for DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINERS?

Recent clinical activity for Diflucan (fluconazole) formulations focuses on IV administration in Dextrose 5% solutions, primarily targeting antifungal indications. As of 2023, no new pivotal trials specifically address the 5% Dextrose in plastic container formulation for Diflucan. Most data derive from existing literature on IV fluconazole safety and efficacy, with ongoing Phase 4 post-marketing surveillance confirming tolerability across a broad patient population.

Clinical Trial Overview

Trial Phase	Number of Trials	Key Focus	Status	Estimated Completion Date
Phase 1	1	Pharmacokinetics, safety	Completed	2021
Phase 2	0	Not reported	Not initiated or ongoing	—
Phase 3	0	Not reported	Not reported	—
Post-Marketing	Several	Safety in diverse populations	Ongoing (Phase 4)	Continues through 2024

No investigational new drug (IND) submissions or phase 3 trials dedicated to reformulations or new delivery containers for Diflucan in Dextrose 5% in plastic have been publicly registered or reported. The emphasis remains on confirming existing data and expanding safety profiles in special populations.

Market Analysis: Size, Segments, and Competitive Landscape

Global Market Size and Forecast

The global antifungal agents market exceeded USD 9 billion in 2022. Expected growth is driven by increasing fungal infections, rising immunocompromised populations, and expanding hospital-acquired infections.

Item	2022 (USD billion)	2028 (Projected, USD billion)	CAGR (2023-2028)	Notes
Total antifungal market	9.2	13.4	7.2%	Growth rate based on industry reports
IV antifungal segment	3.8	5.6	6.9%	Significant due to hospitalization needs

Diflucan (fluconazole) Market Share

• Market Penetration: Diflucan remains the leading oral antifungal, with an approximate 40% share in the IV segment, particularly in the United States and Europe.
• Formulation Focus: The IV formulation in Dextrose 5% is favored in hospitals for systemic candidiasis, cryptococcal meningitis, and other fungal infections.
• Competitive Landscape: Key competitors include amphotericin B, caspofungin, voriconazole, and posaconazole.

Regulatory and Market Access Considerations

• Regulatory Approvals: Diflucan IV in Dextrose 5% is FDA-approved for various indications; no recent amendments specific to container types.
• Packaging Trends: Increasing preference for plastic over glass due to safety, storage, and compatibility advantages.

Drivers and Barriers

• Drivers: Rising fungal infections, expanding hospital stays, and global antimicrobial resistance.
• Barriers: Cost constraints, competitive products with broad spectrum activity, and supply chain issues affecting raw materials.

Market Projection for 2023-2028

• The IV antifungal segment, representing a core part of the overall antifungal market, is projected to grow at a compounded annual growth rate of about 6.9% over the forecast period.
• The specific niche of Diflucan in Dextrose 5% in plastic containers is expected to grow proportionally with hospital procurement trends and advancements in container technology.

Key Trends Affecting Market Outlook

• Container Innovation: Moving from glass to high-grade plastics minimizes breakage risk and enhances patient safety.
• Biosimilar and Generic Entry: Increased competition may stabilize prices, potentially expanding access.
• Economic Factors: Cost pressures may influence the adoption of newer formulations or container types.

Summary and Strategic Implications

While no targeted clinical trials specifically evaluate Diflucan in Dextrose 5% in plastic containers, existing data confirm safety and efficacy for IV use. The market remains robust, underpinned by increasing fungal disease prevalence and hospital utilization. Container innovations favor plastic, supported by safety and logistical advantages. Market share positioning should focus on hospital procurement channels and competitive pricing.

---

Key Takeaways

• No new dedicated clinical trials are underway for Diflucan in Dextrose 5% in plastic containers; existing safety and efficacy data remain the basis for ongoing use.
• The antifungal market is forecasted to grow at a 7.2% CAGR through 2028, driven by rising fungal infection rates.
• The IV antifungal segment, especially hospital-administered formulations, will expand steadily, with container innovation favoring plastics.
• Competition from generics and biosimilars could influence pricing and market share.
• Strategic market growth depends on supply chain resilience, container innovations, and regulatory compliance.

---

FAQs

1. Are there any upcoming clinical trials for Diflucan in new formulations?
No publicly registered clinical trials specifically assess Diflucan in Dextrose 5% in plastic containers beyond post-marketing surveillance. Future trials could focus on enhanced safety or stability, but none are currently planned or announced.

2. How does the market value of Diflucan IV compare globally?
Diflucan remains a top-selling IV antifungal, accounting for about 40% of the IV antifungal market, which is a substantial portion within the broader USD 9 billion antifungal industry.

3. What factors influence the choice of container for Diflucan IV?
Container choice is driven by safety, stability, and logistics. Plastic containers are preferred over glass due to lower breakage risk, compatibility, and ease of disposal.

4. Which regions present the most growth opportunities?
Developing regions with expanding healthcare infrastructure, such as Asia-Pacific and Latin America, offer significant growth due to rising disease burden and increasing hospital capacity.

5. How does the competitive landscape impact Diflucan in the market?
Generic and biosimilar introductions can suppress prices and expand accessibility, but brand loyalty and existing hospital procurement agreements sustain Diflucan’s market share in mature markets.

---

References

1. MarketsandMarkets. (2023). Antifungal Market by Type, Application, and Region.
2. U.S. Food and Drug Administration. (2023). Diflucan (fluconazole) approval details.
3. Grand View Research. (2023). Antifungal Drugs Market Analysis.
4. ClinicalTrials.gov. (2023). Diflucan clinical trials database.
5. Evaluate Pharma. (2023). Global antimicrobial market forecast.